Published in Drug Week, November 25th, 2005
Under the terms of the license, pSivida will manufacture BrachySil and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing, and distribution in China.
Beijing Med-Pharm is a U.S.-based company with Chinese subsidiaries that offers an end-to-end solution to Western pharmaceutical companies that wish to sell their products into the Chinese...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week